Rapid Onset of Inflammatory Bowel Disease after Receiving Secukinumab Infusion

Secukinumab, an interleukin (IL)-17A antagonist, was associated with disease exacerbations in Crohn’s disease, and de novo cases of inflammatory bowel disease (IBD) have been reported in studies of rheumatoid diseases. However, there has been no detailed report demonstrating the linkage between secu...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jingzhou, Bhatia, Arvin, Krugliak Cleveland, Noa, Gupta, Nina, Dalal, Sushila, Rubin, David T., Sakuraba, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American College of Gastroenterology 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6072803/
https://www.ncbi.nlm.nih.gov/pubmed/30105273
http://dx.doi.org/10.14309/crj.2018.56

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6072803/
https://www.ncbi.nlm.nih.gov/pubmed/30105273
http://dx.doi.org/10.14309/crj.2018.56

Ejemplares similares